Mecolvix

Mesalazine, the active ingredient in Mecolvix, is a 5-aminosalicylic acid (5‑ASA) presented as a rectal formulation for local use. It is employed to treat inflammatory disease of the colon, principally ulcerative colitis, in adult patients. GNH USA supplies Mecolvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mecolvix, a 5‑ASA drug, is used within the inflammatory bowel disease therapeutic area to manage ulcerative colitis. - Ulcerative colitis (induction): reduces colonic inflammation to achieve clinical remission. - Ulcerative colitis (maintenance): helps sustain remission and prevent relapse. - Ulcerative proctitis: provides local anti‑inflammatory effect in the distal colon.

Mecolvix may cause a range of adverse reactions, most of which are mild and related to its rectal administration.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea or mild vomiting - Headache - Flatulence or bloating - Diarrhoea

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Acute severe colitis or bloody stools - Hepatic enzyme elevation or liver injury - Pancreatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias such as neutropenia

Before initiating Mecolvix, clinicians should consider several safety measures. - Renal function monitoring: assess baseline creatinine and adjust use if impairment exists. - Hepatic function monitoring: check liver enzymes periodically. - Disease severity assessment: ensure appropriate use in mild‑to‑moderate ulcerative colitis. - Hypersensitivity avoidance: discontinue if allergic reaction occurs. - Pregnancy and lactation: use only if potential benefit outweighs unknown risk. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mecolvix can interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Azathioprine or 6‑mercaptopurine: additive bone‑marrow suppression. - NSAIDs: heightened gastrointestinal irritation.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive efficacy. - Methotrexate: potential additive hepatotoxicity. - Diuretics: may affect renal clearance of mesalazine.